Journal
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
Volume 14, Issue -, Pages 90-94Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jgar.2018.03.004
Keywords
Escherichia coli; Urine culture; Antimicrobials; Resistance; Extended-spectrum beta-lactamase; ESBL
Categories
Ask authors/readers for more resources
Objectives: The aim of this retrospective study was to describe urinary tract infections (UTIs) diagnosed in a single centre in Mexico through 10 years of results, with a particular emphasis on the aetiology, patterns of antimicrobial susceptibility and incidence of extended-spectrum beta-lactamase (ESBL)-producing strains. Methods: This study involved all urine samples analysed during the period March 2007 to September 2017 in a single centre in Mexico. Isolated uropathogens were identified to species level using routine laboratory methods, and antimicrobial susceptibility was determined by the disk diffusion method. Results: Overall, 859 urinary isolates were identified, including 582 (67.8%) Escherichia coli, 69 (8.0%) Enterococcus faecalis, 29 (3.4%) Klebsiella pneumoniae, 24 (2.8%) Proteus mirabilis, 24 (2.8%) Pseudomonas aeruginosa, 23 (2.7%) Candida albicans, 18 (2.1%) Streptococcus agalactiae and 10 (1.2%) Candida glabrata. Patient sex and age were the main risk factors associated with UTI in this population. Nitrofurantoin together with fosfomycin and amikacin had the highest percentages of susceptibility. Of the 859 isolates, 213 (24.8%) presented a positive double-disk synergy test indicating the presence of an ESBL phenotype, with E. coli showing a gradual increase in ESBL-producing isolates over time. Conclusions: These results provide additional evidence in relation to the role of different bacterial species as aetiological agents of UTI as well as antimicrobial susceptibility information that will help to guide the selection of antimicrobial treatment for UTIs and the prevalence of ESBL-producing strains over a 10-year period in a Mexican centre. (C) 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available